Currently out of the existing stock ratings of Richard Law, 44 are a HOLD (47.31%), 43 are a BUY (46.24%), 6 are a SELL (6.45%).

Richard Law

Work Performance Price Targets & Ratings Chart

Analyst Richard Law, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 52.68% that have a potential upside of 43.67% achieved within 188 days. Previously, Richard Law worked at CREDIT SUISSE.

Richard Law’s has documented 184 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VRDN, Viridian Therapeutics at 07-Apr-2026.

Wall Street Analyst Richard Law

Analyst best performing recommendations are on OLMA (OLEMA PHARMACEUTICALS).
The best stock recommendation documented was for OLMA (OLEMA PHARMACEUTICALS) at 11/21/2025. The price target of $26 was fulfilled within 4 days with a profit of $2.83 (12.21%) receiving and performance score of 30.54.

Average potential price target upside

of $20.29 (155.05%) on MLYS (MINERALYS THERAPEUTICS, COMMON STOCK).
of $18.57 (35.38%) on CRSP (CRISPR THERAPEUTICS AG).
of $12.15 (83.68%) on VRDN (VIRIDIAN THERAPEUTICS).

ARVN Arvinas BEAM Beam Therapeutics CRSP Crispr Therapeutics AG FIXX Homology Medicines KYMR Kymera Therapeutics NTLA Intellia Therapeutics EDIT Editas Medicine CCCC C4 Therapeutics GLUE Monte Rosa Therapeutics OLMA Olema Pharmaceuticals VERV Verve Therapeutics MLTX MoonLake Immunotherapeutics RCKT Rocket Pharmaceuticals VRDN Viridian Therapeutics MLYS Mineralys Therapeutics, Common Stock CLDX Celldex Therapeutics SLN Silence Therapeutics PLC ARQT Arcutis Biotherapeutics CRNX Crinetics Pharmaceuticals NUVL Nuvalent

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sudan Loganathan (STEPHENS)